Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.

  • Cano Muñoz, Mario
  • Polo Megías, Daniel
  • Gavira Gallardo, José Antonio
  • Rodríguez López, María J.|||0000-0001-7882-5991
  • Conejero Lara, Francisco|||0000-0002-8282-2168
SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion process, no significant antibody responses against these S2 regions have been reported. Here we designed chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the proteins correlate positively with their structural stability but not with the number of amino acid changes in their HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies., This work was supported by grants CV20.26565 from the Consejería de Economía y Conocimiento, Junta de Andalucía (Spain), PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033), and co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future. The work performed in C.M.’s laboratory was supported by grants from ANRS (Agence Nationale de Recherches sur le SIDA et les h´epatites virales), the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (No. 681032, Horizon 2020). Work in S.B.’s laboratory was supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), the INSERM (UMR_S1109), the Institut Universitaire de France (IUF), all the University of Strasbourg (IDEX UNISTRA), the European Regional Development Fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG) and MSD-Avenir grant AUTOGEN.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes

  • Polo-Megías, Daniel
  • Cano Muñoz, Mario
  • Gantner, Pierre
  • Laumond, Géraldine
  • Decoville, Thomas
  • Grezzani, Jasmine
  • La Rocchia, Ilaria
  • Salinas-García, M. Carmen
  • Cámara-Artigas, Ana
  • Gavira Gallardo, José Antonio
  • Conejero Lara, Francisco|||0000-0002-8282-2168
  • Moog, Christiane
This work was supported by grant PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033 ). Work was further supported by ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d'Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (N°681032, Horizon 2020). P.G. is supported by a research grant from ANRS (N° ECTZ242220) and SIDACTION (N°13709). The work is part of the Doctoral Thesis of Daniel Polo-Megías. Daniel Polo-Megías acknowledges a predoctoral fellowship from the Andalusian Regional Government. Mario Cano-Muñoz was supported by a Postdoctoral Research Program from the Spanish Research Agency: Juan de la Cierva (JDC2022-049681-I). Departamento de Química Física, Instituto de Biotecnología e Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain., The viral envelope glycoprotein (Env) mediates HIV entry to the cell. During this process, its gp41 subunits must assemble into a highly stable six-helix bundle (6HB) by association between their N-terminal and C-terminal heptad repeats (NHR or HR1 and CHR or HR2, respectively), bringing the viral and cell membranes into close proximity. Further interactions involving the gp41 fusion peptide and the membrane proximal external region (MPER) facilitate membrane fusion. Disrupting 6HB formation is a strategy to inhibit HIV. Previously, we re- ported chimeric miniproteins (termed covNHR-N) that mimic the first half of gp41 NHR and potently inhibit HIV- 1. Stabilization of these miniproteins with disulfide bonds was essential for high inhibitory activity. Here, we introduce newly designed covNHR-N miniproteins, further stabilized by polar-to-hydrophobic mutations. Moreover, we incorporated additional structural motifs that interact with the MPER, a target of broadly neutralizing antibodies (bNAbs). These novel miniproteins showed increased binding affinity for gp41-derived peptides and improved HIV-1 inhibitory activity, particularly against infectious primary viruses on peripheral blood mononuclear cells (PBMC). Furthermore, they exhibited strong synergy with bNAbs and reduced HIV-1 replication in ex vivo experiments with cells from infected donors. These miniproteins could be developed as part of drug compositions against HIV-1., SRA/10.13039/501100011033 PID2019.107515RB.C21, ANR-10-LABX-77, EHVA (N°681032, Horizon 2020), ANRS (N° ECTZ242220), SIDACTION (N°13709), Andalusian Regional Government, Spanish Research Agency: Juan de la Cierva (JDC2022-049681-I), Instituto de Biotecnología e Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

  • Beltrán Pávez, Carolina
  • Ferreira, Carolina B.
  • Merino Mansilla, Alberto
  • Fabra García, Amanda
  • Casadella, Maria
  • Noguera Julian, Marc
  • Paredes, Roger
  • Olvera, Alex
  • Haro Villar, Isabel
  • Brander, Christian
  • García Alcaide, Felipe
  • Gatell, José M.
  • Yuste, Eloise
  • Sánchez Merino, Víctor
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

  • Perdiguero, Beatriz
  • Gómez, Carmen E.
  • García-Arriaza, Juan
  • Sánchez-Corzo, Cristina
  • Sorzano, Carlos Óscar S.
  • Wilmschen, Sarah
  • Von Laer, Dorothee
  • Asbach, Benedikt
  • Schmalzl, Christina
  • Peterhoff, David
  • Ding, Song
  • Wagner, Ralf
  • Kimpel, Janine
  • Levy, Yves
  • Pantaleo, Giuseppe
  • Esteban, Mariano
© 2019 Perdiguero, Gómez, García-Arriaza, Sánchez-Corzo, Sorzano, Wilmschen, von Laer, Asbach, Schmalzl, Peterhoff, Ding, Wagner, Kimpel, Levy, Pantaleo and Esteban., The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further refinements of vaccine candidates, formulations, and immunization regimens. Here, we analyzed in mice the immunogenicity profile elicited by different homologous and heterologous prime/boost combinations using the modified rhabdovirus VSV-GP combined with DNA or poxviral NYVAC vectors, all expressing trimeric membrane-bound Env (gp145) of HIV-1 96ZM651 clade C, with or without purified gp140 protein component. In cultured cells infected with recombinant VSV-GP or NYVAC viruses, gp145 epitopes at the plasma membrane were recognized by human HIV-1 broadly neutralizing antibodies (bNAbs). In immunized mice, the heterologous combination of VSV-GP and NYVAC recombinant vectors improved the induction of HIV-1 Env-specific humoral and cellular immune responses compared to homologous prime/boost protocols. Specifically, the combination of VSV-GP in the prime and NYVAC in the boost induced higher HIV-1 Env-specific T cell (CD4/CD8 T cells and T follicular helper -Tfh- cells) immune responses compared to the use of DNA or NYVAC vectors in the prime and VSV-GP in the boost. Such enhanced T cell responses correlated with an enhancement of the Env-specific germinal center (GC) B cell population and with a heavily biased Env-specific response toward the Th1-associated IgG2a and IgG3 subclasses, while the other groups showed a Th2-associated IgG1 bias. In summary, our T and B cell population data demonstrated that VSV-GP-based vectors could be taken into consideration as an optimized immunogenic HIV-1 vaccine candidate component against HIV-1 when used for priming in heterologous combinations with the poxvirus vector NYVAC as a boost., This project had received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 681032 (EHVA, European HIV Vaccine Alliance). The 97CN54 gp140 protein was fully supported by a Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill & Melinda Gates Foundation (Grant ID: 38645) to Dr. Julie McElrath’s group at Fred Hutchinson Cancer Research Center (Seattle, WA, United States).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity

  • Cano-Muñoz, Mario
  • Polo-Megías, Daniel
  • Cámara-Artigas, Ana
  • Gavira Gallardo, J. A.
  • López-Rodríguez, María J.
  • Laumond, Géraldine
  • Schmidt, Sylvie
  • Demiselle, Julien
  • Bahram, Seiamak
  • Moog, Christiane
  • Conejero-Lara, Francisco
SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion process, no significant antibody responses against these S2 regions have been reported. Here we designed chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the proteins correlate positively with their structural stability but not with the number of amino acid changes in their HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies., This work was supported by grants CV20.26565 from the Consejería de Economía y Conocimiento, Junta de Andalucía (Spain), PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033), and co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future”. The work performed in C.M.'s laboratory was supported by grants from ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d'Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (No. 681032, Horizon 2020). Work in S.B.'s laboratory was supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), the INSERM (UMR_S 1109), the Institut Universitaire de France (IUF), all the University of Strasbourg (IDEX UNISTRA), the European Regional Development Fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG) and MSD-Avenir grant AUTOGEN. We are grateful to the Spanish Radiation Synchrotron Source (ALBA), Barcelona, Spain and the European Synchrotron Radiation Facility (ESRF), Grenoble, France, for the provision of time and staff assistance at XALOC (ALBA) and ID30B and ID23-2 (ESRF) beamlines during diffraction data collection. We thank María Carmen Salinas-García for her assistance in carrying out the crystallization screenings. We also thank Pilar González-García for helping us with the statistical analysis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  • Falqui, Michela
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Albert, Manuel
  • Marcos-Villar, Laura
  • McGrail, Joseph Patrick
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen Elena
  • Guerra, Susana
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., This research was supported by the Spanish State Research Agency Ministry of Health of Spain, State secretary of R+D and FEDER/FSE, SAF-2017-88089-R, PDC2021-121307-I00 PID2020- 117425RB-C21 to SG and PID2020-117425RB-C22 to CG; by CIBER consortium, Thematic Area in Infectious Diseases: CIBERINFEC (CB21/13/00108) to CG; by Red Temática de Investigación Cooperativa en Salud: Red Española de Investigación en Sida (RIS) RD16/0025/0014 and in part by European HIV Vaccine Alliance (EHVA) grant ID: 681032 to ME., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Investigating vulnerability of the conserved SARS-CoV-2 spike's heptad repeat 2 as target for fusion inhibitors using chimeric miniproteins

  • Polo-Megías, Daniel
  • Cano-Muñoz, Mario
  • Berruezo, Alberto G.
  • Laumond, Géraldine
  • Moog, Christiane
  • Conejero-Lara, Conejero
© 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Inhibition of SARS-CoV-2 membrane fusion is a highly desired target to combat COVID-19. The interaction between the spike's heptad repeat (HR) regions 1 (HR1) and 2 (HR2) is a crucial step during the fusion process and these highly conserved HR regions constitute attractive targets for fusion inhibitors. However, the relative importance of each subregion of the long HR1-HR2 interface for viral inhibition remains unclear. Here, we designed, produced, and characterized a series of chimeric miniproteins that mimic two different half subdomains of HR1. The proteins were designed as single polypeptide chains that spontaneously fold into antiparallel trimeric helical bundles aimed at structurally imitate the molecular surface of each HR1 half subregion. All the miniproteins folded stably as helical structures and could bind complementary HR2 peptides with moderate affinity. However, only the miniproteins mimicking the N-terminal HR1 half subdomain, but not those imitating C-terminal one, could inhibit cell infection by SARS-COV-2 real viruses in cell cultures. Most interestingly, the inhibitory activity of the miniproteins correlated with their structural stability, but not with their relative binding affinity for HR2 peptides. These results are highly relevant for designing more focused and active fusion inhibitors targeting the highly conserved HR2 region of the Spike., D.P.-M. acknowledges a predoctoral research contract funded by the Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía. This work has been funded the Consejería de Economía y Conocimiento, Junta de Andalucía (Spain) [grant number CV20.26565 ]; the Spanish State Research Agency [grant number PID2019.107515RB.C21/SRA/10.13039/501100011033 ]; and cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future”. The work performed in C.M.'s laboratory was supported by the ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d'Avenir program managed by the ANR [grant number ANR-10-LABX-77]; and EHVA [grant N_681032, Horizon 2020]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes

  • Polo-Megías, Daniel
  • Cano-Muñoz, Mario
  • Gantner, Pierre
  • Laumond, Géraldine
  • Decoville, Thomas
  • Grezzani, Jasmine
  • la Rocchia, Ilaria
  • Salinas-García, M. C.
  • Cámara-Artigas, Ana
  • Gavira Gallardo, J. A.
  • Conejero-Lara, Francisco
  • Moog, Christiane
The viral envelope glycoprotein (Env) mediates HIV entry to the cell. During this process, its gp41 subunits must assemble into a highly stable six-helix bundle (6HB) by association between their N-terminal and C-terminal heptad repeats (NHR or HR1 and CHR or HR2, respectively), bringing the viral and cell membranes into close proximity. Further interactions involving the gp41 fusion peptide and the membrane proximal external region (MPER) facilitate membrane fusion. Disrupting 6HB formation is a strategy to inhibit HIV. Previously, we reported chimeric miniproteins (termed covNHR-N) that mimic the first half of gp41 NHR and potently inhibit HIV-1. Stabilization of these miniproteins with disulfide bonds was essential for high inhibitory activity. Here, we introduce newly designed covNHR-N miniproteins, further stabilized by polar-to-hydrophobic mutations. Moreover, we incorporated additional structural motifs that interact with the MPER, a target of broadly neutralizing antibodies (bNAbs). These novel miniproteins showed increased binding affinity for gp41-derived peptides and improved HIV-1 inhibitory activity, particularly against infectious primary viruses on peripheral blood mononuclear cells (PBMC). Furthermore, they exhibited strong synergy with bNAbs and reduced HIV-1 replication in ex vivo experiments with cells from infected donors. These miniproteins could be developed as part of drug compositions against HIV-1., This work was supported by grant PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033 ). Work was further supported by ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d'Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (N°681032, Horizon 2020). P.G. is supported by a research grant from ANRS (N° ECTZ242220) and SIDACTION (N°13709). The work is part of the Doctoral Thesis of Daniel Polo-Megías. Daniel Polo-Megías acknowledges a predoctoral fellowship from the Andalusian Regional Government. Mario Cano-Muñoz was supported by a Postdoctoral Research Program from the Spanish Research Agency: Juan de la Cierva (JDC2022-049681-I). We are grateful to the Spanish Radiation Synchrotron Source (ALBA), Barcelona, Spain, and the European Synchrotron Radiation Facility (ESRF), Grenoble, France, for the provision of beamtime and staff assistance at XALOC (ALBA, BAG number 2023087670) and ID30B and ID23-2 (ESRF, BAG number MX2650) beamlines during diffraction data collection.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neutralizing nanobodies against SARS-CoV-2 recognizing highly conserved epitopes at the Spike's S2 subunit

  • Polo-Megías, Daniel
  • Cano-Muñoz, Mario
  • Trolese, Philipp
  • Lestani, Sara
  • la Rocchia, Ilaria
  • Pierangelini, Andrea
  • Fongaro, Benedetta
  • de Laureto, P. P.
  • Morales-Yánez, Francisco J.
  • Vaneyck, Jonathan
  • Vanderplasschen, Alain F. C.
  • Decoville, Thomas
  • Laumond, Géraldine
  • Salinas-García, M. C.
  • Cámara-Artigas, Ana
  • Gavira Gallardo, J. A.
  • Moog, Christiane
  • Dumoulin, Mireille
  • Conejero-Lara, Francisco
The formation of a six-helix bundle between the conserved heptad-repeat regions 1 and 2 (HR1 and HR2) in SARS-CoV-2 Spike's S2 subunit is essential for membrane fusion and represents a promising therapeutic target. Previously, we reported recombinant proteins named CoVS-HR1, which mimic the HR1 region and block its interaction with HR2, inhibiting viral fusion. Moreover, they are recognized by plasma antibodies from COVID-19 convalescent patients. In this work, we generated camelid heavy-chain-only antibody fragments (VHHs), also named nanobodies (NBs), against a CoVS-HR1 variant mimicking the full HR1 region. A first generation of selected NBs bound HR1 with high affinity and competed with HR2. Notably, this set of NBs exclusively recognized the C-terminal half of HR1, and two of them showed mild neutralizing activity in cell infection assays. Using a truncated CoVS-HR1 variant (N2C), we selected a second generation of NBs targeting specifically the N-terminal half of HR1. However, these NBs did not demonstrate neutralizing activity, possibly due to their low binding affinities. Several NB epitopes were delineated by hydrogen‑deuterium exchange and mass spectrometry analysis, and the crystal structure of a ternary complex between an HR1-mimetic protein and two NBs was determined, confirming competition with HR2. Intriguingly, we found cooperative binding effects between NBs targeting each half of HR1, but these did not result in detectable inhibitory synergy. These findings demonstrate the existence of neutralizing epitopes in the S2 HR1 region and provide a foundation for future development of enhanced neutralizing NBs focused on specific epitopes using HR1-mimetic proteins., This research was funded by grant PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033). Additional support was provided by ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d'Avenir program administered by the ANR (grant ANR-10-LABX-77), and EHVA (Grant No. 681032, Horizon 2020), with co-funding from the ERDF/ESF under the initiatives “A way to make Europe” and “Investing in your future.” We are also grateful to the Andalusian Regional Government for the predoctoral fellowship awarded to Daniel Polo-Megías. Mario Cano-Muñoz was supported by a Postdoctoral Research Program from the Spanish Research Agency: Juan de la Cierva (JDC2022-049681-I). Francisco Morales-Yáñez was supported by a COS-R funding from the University of Liège. Jonathan Vaneyck was supported by CIP funding. Mireille Dumoulin is a research associate from the FRS-FNRS. We are grateful to the Spanish Radiation Synchrotron Source (ALBA), Barcelona, Spain, and the European Synchrotron Radiation Facility (ESRF), Grenoble, France, for the provision of beamtime and staff assistance at XALOC (ALBA, BAG number 2023087670) and ID30B and ID23-2 (ESRF, BAG number MX2650) beamlines during diffraction data collection. We also acknowledge the Robotein® platform of the BE Instruct-ERIC Centre for providing access to the EasyPick Microlab STARlet Hamilton workstation (https://www.robotein.uliege.be/cms/c_14301428/en/robotein). Funding for open access charge: Universidad de Granada/CBUA.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

  • Beltrán Pávez, Carolina
  • Ferreira, Carolina B.
  • Merino Mansilla, Alberto
  • Fabra García, Amanda
  • Casadella, Maria
  • Noguera Julian, Marc
  • Paredes, Roger
  • Olvera, Alex
  • Haro Villar, Isabel
  • Brander, Christian
  • García Alcaide, Felipe
  • Gatell, José M.
  • Yuste, Eloise
  • Sánchez Merino, Víctor
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.